抗双唾液酸神经节苷脂抗体地努图希单抗联合GM-CSF治疗复发性骨肉瘤的2期研究:儿童肿瘤协作组报告
AOST1421是一项单臂2期研究,评估地努图希单抗联合GM-CSF治疗复发性肺骨肉瘤完全手术缓解患者的疾病控制率(DCR)。39例可评估患者中11例无事件,DCR为28.2%(95%CI 15-44.9%),未达到预设有效性阈值(≥16/39无事件)。结论认为该联合方案未显著改善DCR。
要点
- 地努图希单抗联合GM-CSF治疗复发性骨肉瘤的12个月DCR为28.2%(95%CI 15-44.9%),未达预设有效性阈值。
- 136个治疗周期中1例发生不明原因猝死,符合不可接受毒性标准;其他≥3级毒性包括疼痛、腹泻、缺氧和低血压。
- 两种地努图希单抗输注方案的药代动力学参数相似,青少年和年轻成人患者的毒性和药代动力学与年轻患者相似。
核心结论
- 地努图希单抗联合GM-CSF未显著改善复发性骨肉瘤的疾病控制率。
- 地努图希单抗在青少年和年轻成人骨肉瘤患者中的毒性和药代动力学与年轻患者相似。
- 其他靶向GD2治疗骨肉瘤的策略正在开发中。
研究设计与样本
- AOST1421是一项单臂2期研究,纳入复发性肺骨肉瘤完全手术缓解的患者。
- 患者接受最多5个周期的地努图希单抗(70 mg/m2/周期)联合粒细胞-巨噬细胞集落刺激因子(GM-CSF)。
- 研究两种地努图希单抗输注方案:35 mg/m2/天持续20小时(2天)和17.5 mg/m2/天持续10小时(4天)。
- 主要终点为DCR,定义为入组后12个月无事件患者的比例;历史基准为12个月DCR 20%(95%CI 10-34%)。
- 若≥16/39例患者保持无事件,则认为地努图希单抗有效;39例合格患者纳入结局分析。
主要发现
- 39例患者中11例保持无事件,DCR为28.2%(95%CI 15-44.9%)。
- 136个治疗周期中1个周期因患者发生不明原因猝死而符合不可接受毒性标准。
- 其他≥3级毒性包括疼痛、腹泻、缺氧和低血压。
- 两种输注方案的药代动力学参数相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Novel effective therapies are urgently needed in recurrent osteosarcoma. GD2 is expressed in human osteosarcoma tumours and cell lines. This study evaluated the disease control rate (DCR) in patients with recurrent osteosarcoma treated with the anti-GD2 antibody dinutuximab plus cytokine therapy as compared to historical outcomes. METHODS: AOST1421 was a single-arm Phase 2 study for patients with recurrent pulmonary osteosarcoma in complete surgical remission. Patients received up to five cycles of dinutuximab (70 mg/m2/cycle) with granulocyte-macrophage colony-stimulating factor (GM-CSF). Two different dinutuximab infusion schedules were studied: 35 mg/m2/day over 20 h (2 days) and 17.5 mg/m2/day over 10 h (4 days). Primary end point was DCR, defined as a proportion of patients event free at 12 months from enrolment. The historical benchmark was 12-month DCR of 20% (95% CI 10-34%). Dinutuximab would be considered effective if ≥ 16/39 patients remained event free. Secondary objectives included toxicity evaluation and pharmacokinetics. RESULTS: Thirty-nine eligible patients were included in the outcome analysis. Dinutuximab did not demonstrate evidence of efficacy as 11/39 patients remained event free for a DCR of 28.2% (95% CI 15-44.9%). One of 136 administered therapy cycles met criteria for unacceptable toxicity when a patient experienced sudden death of unknown cause. Other ≥ Grade 3 toxicities included pain, diarrhoea, hypoxia, and hypotension. Pharmacokinetic parameters were similar in the two schedules. CONCLUSIONS: The combination of dinutuximab with GM-CSF did not significantly improve DCR in recurrent osteosarcoma. Dinutuximab toxicity and pharmacokinetics in adolescent and young adult osteosarcoma patients were similar to younger patients. Other strategies for targeting GD2 in osteosarcoma are being developed.
引用
- Hingorani P, Krailo M, Buxton A, et al. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. Eur J Cancer. 2022. PMID: 35809374. doi:10.1016/j.ejca.2022.05.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。